Investigating how genetic changes in IL-17 signaling affect autoimmune diabetes
IL17 Signaling in Monogenic Type 1 Diabetes
['FUNDING_R21'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11120774
This study is looking at how certain genetic changes might affect the immune system and lead to autoimmune diabetes, and it's for families who have a history of this condition to help us learn more about what causes it.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11120774 on ClinicalTrials.gov |
What this research studies
This research aims to explore the role of genetic mutations that impact IL-17 signaling in the development of autoimmune diabetes. By studying individuals and families with suspected monogenic forms of this condition, the research seeks to uncover new biological pathways that contribute to the disease. Advanced genetic sequencing techniques will be employed to identify rare mutations linked to type 1 diabetes, particularly focusing on families with a history of the condition. The findings could enhance our understanding of immune tolerance and the mechanisms leading to pancreatic beta-cell failure.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with monogenic forms of autoimmune diabetes or those with a family history of the condition.
Not a fit: Patients with type 1 diabetes not linked to genetic mutations affecting IL-17 signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights into the causes of autoimmune diabetes and potentially inform targeted therapies.
How similar studies have performed: Previous research has successfully identified genetic mutations linked to autoimmune diabetes, suggesting that this approach has the potential for meaningful discoveries.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GERMAN, MICHAEL S — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: GERMAN, MICHAEL S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diabetes, Autoimmune Diseases